Quantcast

Baron and Budd Attorney Burton LeBlanc Appointed to Plaintiffs’ Steering Committee in GranuFlo, NaturaLyte Litigation

August 20, 2013

Lawsuits Consolidated in Multidistrict Litigation, Will Help Efficiency of Cases

LOS ANGELES (PRWEB) August 20, 2013

Burton LeBlanc, shareholder at the national plaintiffs’ law firm of Baron and Budd, has been selected to sit on the Plaintiffs’ Steering Committee (PSC) in the legal matters surrounding GranuFlo and its sister product NaturaLyte. This committee works to protect the rights of people who have filed lawsuits against Fresenius for health issues allegedly linked to GranuFlo use and supervises activity in the litigation. (IN RE: FRESENIUS GRANUFLO/NATURALYTE. DIALYSATE PRODUCTS LIABILITY LITIGATION. MDL No. 2428, Dist. Of Mass).

“I am honored to have been selected to such a respected group of upstanding attorneys,” said LeBlanc. “I am particularly honored to have the chance to help anyone who has been harmed by GranuFlo use. I’m confident that we will achieve a positive outcome on their behalf.”

LeBlanc is a long-time trial attorney and currently serves as the president of the American Association for Justice (AAJ). He has dedicated his career to protecting the environment and ensuring access to the civil justice system.

GranuFlo and NaturaLyte are products that were frequently used in dialysis treatments in clinics owned and operated by Fresenius Medical Care, the manufacturer of GranuFlo, as well as other dialysis facilities across the country. GranuFlo contains an ingredient that metabolizes in the body as bicarbonate. The FDA issued a recall on the products claiming that they caused elevated levels of bicarbonate in the blood with an increased risk of heart attacks as well as other serious health issues. http://www.fda.gov/medicaldevices/safety/listofrecalls/ucm309990.htm

Fresenius Medical Care was allegedly aware of these possibly harmful side effects. An internal company memo was anonymously sent to the U.S. Food and Drug Administration (FDA) as evidence of the company’s knowledge. Yet Fresenius allegedly failed to immediately alert users of Granuflo and NaturaLyte about these dangers.

http://www.nytimes.com/2012/06/15/health/fda-investigates-fresenius-for-failure-to-warn-of-risk.html?_r=0

(http://www.fda.gov/medicaldevices/safety/listofrecalls/ucm309990.htm)

For decades, the national plaintiffs’ law firm of Baron and Budd has been actively handling pharmaceutical litigation. The firm presently represents thousands of clients who have been allegedly harmed by the use of the diabetes drug Avandia. The firm also represents litigation involving the marketing of Avandia in numerous states. (In Re: Avandia Marketing, Sales Practices and Products Liability Litigation, MDL No. 1871, E.D. Pa.) Previously, Baron and Budd was involved in negotiating a global settlement totaling $1.275 billion on behalf of people who had been harmed by using diet drug Fen-Phen. (In re Diet Drugs (Phentermine | Fenfluramine | Dexfenfluramine) Products Liability Litigation, Case No. 98- MDL No. 1203 (E.D. Pa.)

Baron and Budd is currently handling lawsuits related to GranuFlo, Lipitor, Actos and Transvaginal Mesh. To find out if you have a case, call us at 1.866.844.4556 or visit http://baronandbudd.com/areas-of-practice/pharmaceuticals/granuflo-lawyer/.

About Baron & Budd

With offices in Dallas, Austin, Baton Rouge and Los Angeles, Baron and Budd is a nationally recognized law firm with more than 35 years of experience “Protecting What’s Right” for people, businesses and communities harmed by negligence corporations and practices. Because of Baron and Budd’s size and resources, the law firm is capable of handling large and complex cases. Baron and Budd represents both individuals and governmental and business entities in areas as diverse as mesothelioma caused by asbestos exposure, deceptive advertising, harmful drugs, medical devices, FLSA violations, toxic exposure, the Gulf oil spill, consumer financial fraud and water contamination.

For the original version on PRWeb visit: http://www.prweb.com/releases/2013/8/prweb11033468.htm


Source: prweb



comments powered by Disqus